Fubotv earnings beat by $0.10, revenue topped estimates
LONDON - AstraZeneca PLC (LSE/STO/Nasdaq: LON:AZN), a global biopharmaceutical company, today announced upcoming changes to its board of directors. Karen Knudsen is set to be proposed for election as a Non-Executive Director at the company's Annual General Meeting scheduled for April 11, 2025. If elected, Knudsen will join the Science Committee and the Sustainability Committee.
Knudsen, recognized as a leading cancer scientist with extensive executive experience in oncology, has served as CEO of the American Cancer Society and held leadership roles at Thomas Jefferson University and the Sidney Kimmel Comprehensive Cancer Center. Her expertise is expected to contribute significantly to AstraZeneca (NASDAQ:AZN)'s focus areas, particularly in oncology.
The company also disclosed that Non-Executive Directors Deborah DiSanzo and Andreas Rummelt will not be seeking re-election and will retire from the board following the AGM. DiSanzo has been part of the board since 2017, while Rummelt joined in 2021 after AstraZeneca's acquisition of Alexion (NASDAQ:ALXN).
Furthermore, Diana Layfield, already serving as a Non-Executive Director, will become a member of the Remuneration Committee starting May 1, 2025.
Michel Demaré, Chair of AstraZeneca, expressed gratitude towards the departing members for their contributions and welcomed Knudsen's potential addition, highlighting her deep knowledge of the US healthcare industry and medical academic environment.
The press release did not require any additional disclosures under the UK Financial Conduct Authority's Listing Rules regarding Knudsen's appointment.
Headquartered in Cambridge, UK, AstraZeneca specializes in prescription medicines across various therapeutic areas, with its products reaching over 125 countries worldwide.
This article is based on a press release statement from AstraZeneca PLC.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.